AC Immune (ACIU) Releases Quarterly Earnings Results, Misses Estimates By $0.36 EPS

AC Immune (NASDAQ:ACIU) announced its quarterly earnings data on Wednesday. The company reported $0.84 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.36), MarketWatch Earnings reports. The firm had revenue of $75.28 million during the quarter, compared to the consensus estimate of $106.81 million. AC Immune had a negative net margin of 706.11% and a negative return on equity of 33.97%.

AC Immune stock traded up $0.09 during midday trading on Thursday, hitting $5.16. The stock had a trading volume of 9,625 shares, compared to its average volume of 500,413. The firm has a market cap of $346.60 million, a P/E ratio of -6.29 and a beta of 0.01. AC Immune has a 12 month low of $3.25 and a 12 month high of $17.40.

Several analysts recently weighed in on the company. BidaskClub raised AC Immune from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 9th. Zacks Investment Research lowered AC Immune from a “buy” rating to a “hold” rating in a report on Monday, April 8th. Finally, ValuEngine lowered AC Immune from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. AC Immune presently has a consensus rating of “Buy” and an average price target of $11.94.

COPYRIGHT VIOLATION WARNING: “AC Immune (ACIU) Releases Quarterly Earnings Results, Misses Estimates By $0.36 EPS” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Further Reading: How to read a candlestick chart

Earnings History for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with's FREE daily email newsletter.